TrialVaccine2021

A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine.

Laurence Chu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.